文献速递心境障碍精神分裂症与精神病性障碍儿童青少年精神

宫内抗精神病药暴露与先天畸形风险:北欧五国与美国队列研究

Association of In Utero Antipsychotic Medication Exposure With Risk of Congenital Malformations in Nordic Countries and the US.
PubMed 文献 · JAMA Psychiatry · 2023-01-01

IMPORTANCE: Psychiatric disorders are common among female individuals of reproductive age. While antipsychotic medication use is increasing, the safety of such medications in pregnancy is an area with large evidence gaps.…

要点

  • 宫内抗精神病药暴露总体未显著增加重大先天畸形风险。
  • 奥氮平与口腔裂的aRR为2.1(95%CI 1.1-4.3),敏感性分析结果不一。
  • 非典型药与腹裂、特定脑异常及氯普噻吨与心脏畸形关联需进一步确认。

核心结论

  • 宫内抗精神病药暴露总体与重大先天畸形风险无有意义的关联。
  • 奥氮平与口腔裂、非典型药与腹裂及特定脑异常、氯普噻吨与心脏畸形的风险升高需累积证据确认。

研究设计与样本

  • 基于北欧五国与美国全国健康登记数据的队列研究,跨度1996至2018年。
  • 北欧队列纳入所有单胎活产妊娠,美国队列为Medicaid Analytic eXtract中公开保险母亲与其活产婴儿。
  • 暴露为妊娠早期配发任何非典型、任何典型或个体抗精神病药。
  • 采用倾向评分分层控制混杂,间接标准化计算合并调整估计。

主要发现

  • 未暴露组重大畸形患病率2.7%(95%CI 2.7%-2.8%),非典型药暴露组4.3%(95%CI 4.1%-4.6%),典型药暴露组3.1%(95%CI 2.7%-3.5%)。
  • 常见暴露-结局组合的调整相对风险(aRR)总体接近无效值。
  • 奥氮平与口腔裂aRR为2.1(95%CI 1.1-4.3),但敏感性分析结果不一。
  • 非典型药暴露与腹裂aRR为1.5(95%CI 0.8-2.6)、与其他特定脑异常aRR为1.9(95%CI 1.1-3.0)。
  • 氯普噻吨暴露与心脏畸形aRR为1.6(95%CI 1.0-2.7)。

临床怎么用

  • 临床咨询时应告知孕妇抗精神病药暴露总体未显著增加重大畸形风险。
  • 对奥氮平、非典型药及氯普噻吨的特定畸形信号需个体化权衡,避免过度解读。

局限性

  • 极罕见暴露-结局组合存在不可避免的统计噪声。
  • 部分关联置信区间宽,无法得出确切结论。
  • 观察性设计可能残留混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Psychiatric disorders are common among female individuals of reproductive age. While antipsychotic medication use is increasing, the safety of such medications in pregnancy is an area with large evidence gaps. OBJECTIVE: To evaluate the risk of first-trimester antipsychotic exposure with respect to congenital malformations, focusing on individual drugs and specific malformation subtypes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from nationwide health registers from the 5 Nordic countries and the US and spanned 1996 to 2018. The Nordic cohort included all pregnancies resulting in singleton live-born infants, and the US cohort consisted of publicly insured mothers linked to their live-born infants nested in the nationwide Medicaid Analytic eXtract. Data were analyzed from November 2020 to April 2022. EXPOSURES: One or more first-trimester dispensing of any atypical, any typical, and individual antipsychotic drugs. MAIN OUTCOMES AND MEASURES: Any major congenital malformation and specific malformation subtypes previously suggested to be associated with antipsychotic exposure in utero: cardiovascular malformations, oral clefts, neural tube defects, hip dysplasia, limb reduction defects, anorectal atresia/stenosis, gastroschisis, hydrocephalus, other specific brain anomalies, and esophageal disorders. Propensity score stratification was used to control for potential confounders. Pooled adjusted estimates were calculated using indirect standardization. RESULTS: A total of 6 455 324 unexposed mothers (mean maternal age range across countries: 24-31 years), 21 751 mothers exposed to atypical antipsychotic drugs (mean age range, 26-31 years), and 6371 mothers exposed to typical antipsychotic drugs (mean age range, 27-32 years) were included in the study cohort. Prevalence of any major malformation was 2.7% (95% CI, 2.7%-2.8%) in unexposed infants, 4.3% (95% CI, 4.1%-4.6%) in infants with atypical antipsychotic drug exposure, and 3.1% (95% CI, 2.7%-3.5%) in infants with typical antipsychotic drug exposure in utero. Among the most prevalent exposure-outcome combinations, adjusted relative risks (aRR) were generally close to the null. One exception was olanzapine exposure and oral cleft (aRR, 2.1 [95% CI, 1.1-4.3]); however, estimates varied across sensitivity analyses. Among moderately prevalent combinations, increased risks were observed for gastroschisis and other specific brain anomalies after atypical antipsychotic exposure (aRR, 1.5 [95% CI, 0.8-2.6] and 1.9 [95% CI, 1.1-3.0]) and for cardiac malformations after chlorprothixene exposure (aRR, 1.6 [95% CI, 1.0-2.7]). While the association direction was consistent across sensitivity analyses, confidence intervals were wide, prohibiting firm conclusions. CONCLUSIONS AND RELEVANCE: In this study, considering the evidence from primary and sensitivity analyses and inevitable statistical noise for very rare exposure-outcome combinations, in utero antipsychotic exposure generally was not meaningfully associated with an increased risk of malformations. The observed increased risks of oral clefts associated with olanzapine, gastroschisis, and other specific brain anomalies with atypical antipsychotics and cardiac malformations with chlorprothixene requires confirmation as evidence continues to accumulate.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Huybrechts KF, Straub L, Karlsson P, et al. Association of In Utero Antipsychotic Medication Exposure With Risk of Congenital Malformations in Nordic Countries and the US. JAMA Psychiatry. 2023. PMID: 36477338. doi:10.1001/jamapsychiatry.2022.4109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。